Everything below concerns preclinical model. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-01-17. Numbers and descriptions here follow the published literature rather than marketing material.
Several mechanisms have been proposed to explain the activity observed in animal models. The most frequently cited involve signaling through vascular endothelial growth factor receptor 2 and modulation of the nitric oxide system. Researchers have also described interactions with protective pathways in the gut lining. These proposed mechanisms appear in the literature as hypotheses supported by preclinical observations, not as confirmed pathways in humans. The precise way the peptide produces its reported effects, and whether those effects carry across species, remain areas of active and unresolved investigation.
BPC-157 is a synthetic pentadecapeptide, meaning it consists of fifteen amino acids joined in a single chain. Its sequence is Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val, a fragment corresponding to part of a larger protein found in human gastric juice. The peptide was first described in the 1990s by researchers in Zagreb who were studying gastric protective factors. It is not a naturally circulating hormone; it is a laboratory-made fragment derived from a stomach protein. The name is an abbreviation of body protection compound, with the number referring to the fragment's position in the source protein.
Most published work on BPC-157 comes from animal experiments rather than controlled human trials. Rodent models have examined its effects on gastrointestinal lesions, tendon and ligament injury, and blood vessel formation. These studies are often small and originate from a limited number of research groups, which affects how broadly the findings can be generalized. No large randomized human trial has been reported in the peer-reviewed literature. Discussion of the compound therefore rests largely on preclinical data, and questions about its effects in people remain open rather than settled.
Most published findings come from rodent experiments using induced injury or surgical models. Human reports remain scarce and are largely observational, which limits how much can be stated with confidence. Questions about absorption, distribution, metabolism, and clearance in people are still open. Dose translation between species is likewise unresolved. Researchers tend to read the animal literature as a starting point rather than a settled account.
BPC-157 is a synthetic peptide composed of fifteen amino acids. Its sequence corresponds to part of a protein found in human gastric juice, which is the origin of the "body protection compound" label. In laboratory work the material is treated as a defined research chemical rather than a finished product. Published research has centered on animal models, and the peptide is not an approved medicine in most countries.
The peptide was first described in the early 1990s by a group studying gastric secretions and tissue repair. Its fifteen-residue chain is usually written as GEPPPGKPADDAGLV in single-letter code. The free peptide has the formula C62H98N16O22 and a theoretical mass near 1419.5 daltons. These identifiers are established chemical facts that can be checked against standard peptide databases. There is no ambiguity about the primary structure.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic pentadecapeptide | Composed of fifteen amino acid residues |
| Amino acid sequence | Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val | Single-letter form GEPPPGKPADDAGLV |
| Original source | Fragment of a protein in human gastric juice | First characterized in the 1990s |
| Number in name | 157 | Refers to the fragment's position in the source protein |
| Human trial evidence | Limited | Preclinical rodent data predominate |
Some properties, such as the peptide's sequence and molecular mass, are firmly established. Other claims, particularly about mechanism and clinical benefit, remain open questions. Proposed mechanisms include effects on nitric oxide signaling and on cell migration, but these are hypotheses supported by limited evidence. Reviewers often note that the field lacks large controlled human trials. Positive animal findings are best treated as signals for further study rather than as settled conclusions.
Most published studies examine BPC-157 in animal models rather than in humans. Common subjects include rats and mice, and researchers often use models of tissue injury, surgery, or induced inflammation. Reported endpoints include healing rates, blood vessel formation, and markers of tissue repair. These designs provide controlled comparisons, but findings in animals do not automatically transfer to people. Human clinical data remain limited and are frequently described as preliminary.
Doses in the literature are usually expressed in micrograms or nanograms per kilogram of body weight. Investigators have administered the peptide by several routes, including injection and oral delivery, depending on the question asked. Route and dose vary widely across studies, which complicates direct comparison of results. Many papers report effects at low doses, but the absence of a standardized protocol limits generalization. Reporting practice differs between research groups.
Material of this kind is sold for laboratory research, and labels typically state that it is not intended for human or veterinary use. In many countries it is not an approved medicine, and sports antidoping rules place it among prohibited non-approved substances. Buyers commonly review a certificate of analysis, an independent test report, and the declared storage conditions. Batch-to-batch variation in purity and in counterion content is possible, and how much that variation affects experimental outcomes remains an open question.
Lyophilized peptide is normally kept at minus twenty degrees Celsius or colder, away from light and moisture. Powder held under those conditions is widely treated as stable for long periods, although published stability studies for this exact sequence are sparse and often come from suppliers rather than independent laboratories. Once dissolved, solutions are generally handled cold and used within a short window, because peptide bonds can hydrolyze over time. Repeated freeze-thaw cycles are usually avoided to limit losses, and exact shelf-life figures depend on the buffer and the concentration involved.
Purity is ordinarily reported as a percentage from reverse-phase high-performance liquid chromatography, where the area of the main peak is compared with the total peak area. Identity is confirmed by mass spectrometry, since the measured mass can be checked against the value calculated from the sequence. Some certificates also include amino acid analysis or sequence confirmation by tandem mass spectrometry. A single purity number does not describe the profile of related impurities, so the underlying chromatogram and spectrum usually carry more information than the headline figure.
Published storage guidance follows general peptide practice rather than product-specific studies. The dry powder is typically kept at minus 20 degrees Celsius, away from light and moisture. Once reconstituted, solutions are generally refrigerated and used over days to weeks, because the aqueous environment slowly promotes hydrolysis and oxidation. Long-term data on degradation rates or breakdown products are sparse. Stated shelf lives from different producers vary widely, reflecting the absence of a shared reference standard.
BPC-157 is a synthetic peptide built from fifteen amino acid residues. Its sequence comes from a larger protein fragment that researchers isolated from human gastric juice and described as a body protection compound. The fragment contains glycine, glutamic acid, five prolines, lysine, alanine, two aspartic acids, leucine, and valine. The number 157 in the name refers to the position of the stretch within the parent protein. Material used in laboratories is manufactured rather than extracted from stomach fluid.
The molecule carries 15 residues, a molar mass near 1419.5 g/mol, and the formula C62H98N16O22. Its structure features a proline-rich central region, a pair of adjacent aspartic acid residues, and no cysteine. The absence of cysteine means no disulfide bonds can form, which simplifies refolding and reconstitution. Suppliers usually ship the material as a freeze-dried powder that appears white to off-white. It dissolves readily in water and in saline solutions.
Terminology in the literature is not fully standardised. Papers and product listings use BPC-157, BPC 157, and the longer phrase stable gastric pentadecapeptide BPC 157 interchangeably, and synonyms such as bepecin or PL 14736 appear in older or company-linked publications. Purity claims and reported masses can also differ between sources because peptide preparations may include counterions, residual solvents, or bound water. This variability complicates direct comparison of results across studies and makes the exact identity and grade of a given sample worth verifying. Discussions of the compound should therefore specify the source, salt form, and stated purity where those are known.
BPC-157 is a synthetic peptide composed of fifteen amino acid residues, with the sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. Its name derives from body protection compound, a term used for a protein fraction identified in human gastric juice. Researchers in Zagreb first reported the pentadecapeptide in the early 1990s and described it as a stable fragment of that larger protein. The compound is also catalogued as PL 14736 and, in some commercial contexts, as bepecin. Its molecular formula is C62H98N16O22 and its monoisotopic mass is approximately 1419 daltons.
Most published work on BPC-157 consists of preclinical studies, including rodent models of tissue injury, gastrointestinal lesions, and vascular or tendon damage, together with in vitro cell assays. Reviews frequently note that the mechanisms proposed in these papers remain incompletely characterised and that findings have not been confirmed in large randomised human trials. The compound is widely sold as a research chemical rather than a licensed medicine, and labels commonly carry a statement that it is not for human use. Whether any of the reported animal effects translate to humans is an open question rather than an established result.
Glutamatergic means "involving the release of, or activated by, glutamate". A glutamatergic agent (or drug) is a chemical that directly modulates the excitatory amino acid (glutamate/aspartate) system in the body or brain. Examples include:
=== Affinity therapy === Affinity therapy, or immunotoxins is a biorecognition-based approach to selectively deliver a cytotoxic drug or toxin to a specific target cell. The field of affinity therapy was pioneered by Wilchek, together with Michael Sela, Ester Hurwitz, and Ruth Arnon. In 1975, they applied drug-conjugated antibodies for the targeted delivery of cytotoxic compounds to cancer cells. They also demonstrated the advantage of having a polymeric spacer between the antibody and the drug and showed the effectiveness of conjugating simple polymers such as dextran for drug delivery and targeting. This approach was later adopted by others and eventually led to efficient treatment of human breast cancer by recombinant humanized anti-HER2 antibody (Herceptin) in a mixture with paclitaxel and doxorubicin. In 2003, Wilchek collaborated in a team who introduced a system based on antibody-directed enzyme prodrug therapy (ADEPT), using antibody-conjugated alliinase to produce a cytotoxic agent, allicin, in situ (at the site) of the cancer
=== Children === Levothyroxine is safe and effective for children with hypothyroidism; the goal of treatment for children with hypothyroidism is to reach and preserve normal intellectual and physical development.
Map of Mexican drug war violence Borderland Beat Blog dedicated to reporting on Mexican drug cartels on the border between the US and Mexico Bowers, Charles (2009). "The Mexican Kidnapping Industry". Archived from the original on February 23, 2015. Retrieved April 9, 2009. An academic paper examining both the emergence of kidnapping as a drug war spillover, and statewide variance in Mexico's kidnapping statutes. The Mexican Zetas and Other Private Armies – written by the Strategic Studies Institute. Mexico page on InSight Crime. Ongoing reporting on Mexico's drug war and the involved cartels. "Full Coverage Mexico Under Siege". Los Angeles Times. Archived from the original on April 6, 2014. Retrieved September 12, 2016. The Atlantic: Mexico's Drug War George Grayson, "Mexico's Elite Must Commit to Fighting Drug Cartels", Foreign Policy Association Headline Series. Juarez, City of Death, City of Hope Cocaine Incorporated June 15, 2012 How American guns turned Mexico into a war zone (by Stuart Miller, LA Times, February 24, 2021)
== Methodology == Operando spectroscopy is a class of methodology, rather than a specific spectroscopic technique such as FTIR or NMR. Operando spectroscopy is a logical technological progress in situ studies. Catalyst scientists would ideally like to have a "motion picture" of each catalytic cycle, whereby the precise bond-making or bond-breaking events taking place at the active site are known; this would allow a visual model of the mechanism to be constructed. The ultimate goal is to determine the structure-activity relationship of the substrate-catalyst species of the same reaction. Having two experiments—the performing of a reaction plus the real-time spectral acquisition of the reaction mixture—on a single reaction facilitates a direct link between the structures of the catalyst and intermediates, and of the catalytic activity/selectivity. Although monitoring a catalytic process in situ can provide information relevant to catalytic function, it is difficult to establish a perfect correlation because of the current physical limitations of in situ reactor cells. Complications arise, for example, for gas phase reactions which require large void volumes, which make it difficult to homogenize heat and mass within the cell. The crux of a successful operando methodology, therefore, is related to the disparity between laboratory setups and industrial setups, i.e., the limitations of properly simulating the catalytic system as it proceeds in industry.
Sources: en.wikipedia.org
=== Mechanism of action === The mechanism of action of bismuth is not fully known. It has been reasoned to interfere with the function of the bacterial cell membrane, protein and cell wall synthesis, the enzyme urease, cell adhesion, ATP synthesis, and iron transport mechanisms. Bismuth displaces nickel (Ni2+) from active sites of the bacterial urease (UreG), and other bacterial metalloenzymes (e.g., catalase, lipase, fumarase), thereby disrupting acid-neutralization capacity and energy metabolism of H. pylori. Another possible mechanism of action is that the inhibition of bacterial enzyme result in bacterial growth arrest. Bismuth particles induce vacuolization, cell wall degradation, membrane disintegration, and loss of adherence to epithelial cells of the host: bismuth impairs bacterial adhesion to the gastric epithelium and biofilm formation.
=== Radiation therapy === Radiation therapy is the most frequently used treatment for hypersomatotropic cats. Radiation therapy is expensive, limited in availability, cost, frequent anaesthetic, and the unpredictable outcomes for hormonal control. The resolution or improvement of neurological signs is the most consistent effect. Improvement diabetes symptoms is less consistent. One study found an average of 5 weeks for improvement to glycaemic control with all cats seeing an improvement within 20 weeks. The same study found 6 of the 14 cats to achieve diabetic remission within 6 months with an average of 3.6 months. Diabetic remission may occur as late as a year after radiotherapy. Improvement of diabetic symptoms occurs in roughly 70-80% of cases, diabetic remission occurs in roughly 50%. The physical acromegalic changes often persistent or have only slight improvement. High IGF-1 levels have been reported in cats following radiation therapy. Of note is that in several of those cases the patient had good control of diabetic symptoms or was in remission. Radiation therapy is tolerated by the majority of cats. Side effects such as ischaemic brain necrosis and hearing loss are rare and proper fractionation protocol can prevent these effects from occurring; hypopituitarism has not been reported in cats, despite being a common adverse effect in humans. Survival times for cats after radiation therapy has been reported to be up to 5 years.
== In popular culture == The 1960 British war film Sink the Bismarck! discusses the strategic importance of the GIUK gap during World War II naval operations in the Atlantic theatre, and depicts the Battle of the Denmark Strait between British and German forces. It is based on the novel The Last Nine Days of the Bismarck by C. S. Forester. The GIUK line is mentioned in the film The Bedford Incident. In Tom Clancy's first novel, The Hunt for Red October, the line was used to detect Soviet submarines entering the North Atlantic in pursuit of the rogue Typhoon-class submarine Red October, whose officers were defecting to the United States with clandestine stealth technology. The event causes significant political and military tension between the United States and the Soviet Union. The film adaptation also references the gap, with National Security Advisor Jeffrey Pelt (played by Richard Jordan) saying to the Soviet ambassador "Your aircraft have dropped enough sonar buoys so that a man could walk from Greenland to Iceland to Scotland without getting his feet wet." In Clancy's second novel, Red Storm Rising, the line is featured more prominently after a war breaks out between NATO and the Warsaw Pact. The Soviet Union launches a surprise attack on the NATO airbase NAS Keflavik and invades Iceland. This causes the line to be destroyed, creating a gap in NATO's surveillance and allowing the Soviet Navy to enter the North Atlantic.
== See also == Advanced Landing Ground – a type of semi-permanent bases in Kent, France, Belgium, Netherlands and occupied Germany Air Ministry Experimental Station Chain Home – radar defence system developed during the Second World War Class A airfield – airfields constructed to Air Ministry specifications during the Second World War List of Battle of Britain airfields List of North African airfields during World War II List of Royal Air Force stations, current MoD and RAF stations List of Royal Air Force Satellite Landing Grounds List of V Bomber dispersal bases
The character of GLaDOS, voiced by Ellen McLain, received acclaim for her unique characterization and the end credits song "Still Alive", written by Jonathan Coulton, was praised for its original composition and humor. Portal is often cited as one of the greatest video games ever made. Excluding Steam download sales, over four million copies have been sold, spawning merchandise from Valve including a model portal gun and plush Companion Cubes, as well as fan recreations of the cake. A standalone version with extra puzzles, Portal: Still Alive, containing many recreated levels from a fan-made flash game, was published by Valve on the Xbox Live Arcade service in October 2008 for Xbox 360. A sequel, Portal 2, was released in 2011, which expanded on the storyline, added several gameplay mechanics, and included a cooperative multiplayer mode and level creator. A port for the Nintendo Switch was released as part of the Portal: Companion Collection in June 2022, which included the additional levels from the Still Alive release of the game. On December 8, 2022, a free remaster developed by Nvidia's Lightspeed Studios with Valve's permission was published on Steam under the name Portal with RTX in order to showcase Nvidia's RTX Remix tool.
Sources: en.wikipedia.org
It is a chain of fifteen amino acids, referred to as a pentadecapeptide. The sequence is Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. It corresponds to a fragment of a protein found in human gastric juice.
It is neither a naturally circulating hormone nor an approved medicine in most countries. It is a synthetic peptide fragment used chiefly as a laboratory research material. Its regulatory status varies by jurisdiction, and it is not authorized as a therapeutic product in the United States or the European Union.
Published human evidence is very limited. Most findings come from rodent studies conducted by a small number of groups. As a result, statements about its effects in humans are generally described as uncertain rather than established.
The peptide is synthetic, but its sequence matches a segment of a protein present in human gastric juice. It does not occur as a free fifteen-residue peptide in the body.